Actively Recruiting
Combination of TATE and PD-1 Inhibitor in Liver Cancer
Led by Teclison Ltd. · Updated on 2026-04-16
54
Participants Needed
3
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.
CONDITIONS
Official Title
Combination of TATE and PD-1 Inhibitor in Liver Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with confirmed advanced hepatocellular carcinoma or metastatic gastric cancer
- Age between 18 and 80 years
- Progressive disease on prior immune checkpoint inhibitor for HCC or failure of at least one chemotherapy and immune checkpoint inhibitor for gastric cancer
- Presence of liver tumor lesions with at least one lesion 2 cm or larger suitable for selective TATE treatment
- ECOG performance status of 2 or less
- Child-Pugh score between 5 and 7 for HCC patients
- At least 4 weeks since prior chemotherapy (immunotherapy timing not restricted)
- Hemoglobin level of 8 g/dL or higher, platelet count of 50,000 or more, creatinine 2 or less, AST and ALT less than 10 times the upper limit, total bilirubin less than 3
You will not qualify if you...
- History of major autoimmune disorders
- Major gastrointestinal bleeding within the past 2 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
University of California, Irvine
Orange, California, United States, 92868
Actively Recruiting
2
University of Oklahoma Health Science Center
Oklahoma City, Oklahoma, United States, 73104
Actively Recruiting
3
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
Research Team
R
Ray Lee, MD. PhD
CONTACT
C
Chiwei Lu, PhD.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here